[Chengda Biotech: Signed Recombinant Tetravalent Enterovirus Vaccine Technology Transfer Contract] On September 24, Chengda Biotech (688739.SH) announced that the company signed a "Recombinant Quadrivalent Enterovirus Vaccine Technology Transfer Contract" with Wiltek, and transferred all rights and interests of the recombinant quadrivalent enterovirus vaccine (Hansenula yeast) project. The technology transfer fee is 46 million yuan (tax included), which will be paid in installments based on milestones; sales commissions and sales milestone rewards will be paid based on the sales of the product after it is launched. The subject product is still in the early stages of research and development, and there are uncertainties in subsequent clinical trials, registration approval and commercialization.